Cesarean Section ComplicationsPhase 4NCT05264870
Norepinephrine in Caesarian Section
A Phase 4 study testing Norepinephrine in people with Cesarean Section Complications and Hemodynamic Instability, run by University Hospital, Antwerp at 1 site in Belgium.
Trial summary
Postspinal hypotension is a frequent maternal complication in caesarian delivery under neuraxial anesthesia which is most commonly treated with the administration of phenylephrine infusion. In this trial, postspinal hypotension will be treated with norepinephrine. Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Cesarean Section Complications, Hemodynamic Instability, Foetal Stress
- What is being tested?
- Norepinephrine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 11 participants
- Where
- 1 siteBelgium
- Study dates
- 9 Jun 2022to 27 Aug 2025
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- American Society of Anesthesiologists classification (ASA)1 and 2 patients
- non-laboring and singleton pregnancy
Who cannot join
- patients with cardiovascular comorbidities
- any kind of cardiac and peripheral vascular disease or diabetes
- history of coagulopathy
- contra-indication to spinal anesthesia
- allergic condition to vasopressors or local anesthetics
- total body weight under 50kg or above 100kg
- length under 150cm and over 180cm Body Mass Index (BM)I ≥ 32
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Norepinephrine as Hemodynamic Maintenance in Caesarian Delivery Under Spinal Anesthesia
Postspinal hypotension is a frequent maternal complication in caesarian delivery under neuraxial anesthesia which is most commonly treated with the administration of phenylephrine infusion. In this trial, postspinal hypotension will be treated with norepinephrine. The main objective is to examine the pharmacodynamic and biochemical effect of norepinephrine both on mother and newborn.
Read the detailed description
Patients scheduled for routine elective cesarean section under combined spinal epidural anesthesia (CSE)will be enrolled in this double-blind, randomized controlled trial, As standard of care for cesarean section procedure, a preoperative anesthetic consultation is performed. If the patient is eligible for enrollment, she will be provided with detailed information regarding the study and asked to sign Informed Consent. Participants are allocated to one of two groups: Group A will receive a CSE anesthesia with 7,5 milligrams (mg)hyperbaric Marcaine and 2,5 microgram (mcg)Sufentanil.
Group B will receive a CSE anesthesia as well with 10 mg hyperbaric Marcaine and 2,5 mcg Sufentanil. At the University Hospital Antwerp, Group A is standard of care for cesarean section. In case of insufficient pain relief an extra bolus of local anesthesia through the epidural catheter can be administered in both groups. In this trial we use a double blinding principle. Both the patient and the observant/study physician are fully blinded. To maintain blinding of the study, two anesthesiologists are involved in this trial. The first anesthesiologist will perform randomization by means of Redcap software and will prepare study medication according to allocation to group A or B just before start of spinal anesthesia. He /she is responsible for the placement of neuraxial block and the spinal epidural catheter. As part of routine care anesthesia an intravenous line with 500 milliliter (ml) Plasmalyte (minimal 20 Gauche catheter) will be established in both groups . Standard monitoring (blood pressure, Electrocardiogram and Oxygen saturation) will be applied.
A baseline systolic blood pressure will be measured as a mean of 3 consecutive measurements before start of CSE and is defined as baseline blood pressure.
Blood pressure will be measured every 1 minute. To maintain normotension during the procedure a continuous infusion of norepinephrine will be given at 15 milliliter/hour through the peripheral intravenous (IV)catheter in both groups. Therefore a solution of norepinephrine in a concentration of 10mcg/ml in a 50ml syringe is prepared and connected to the peripheral IV line, most proximal to the IV catheter. A combined spinal epidural puncture will be performed in the sitting position at the level of Lumbal (L)2-L3 or L3-L4 with a CSE needle set (18 Gauge Tuohy needle, 27 Gauge pencil point needle, 18 gauge catheter, Braun).
After placing the 18-gauge Tuohy needle in the epidural space, confirmed by loss of resistance with natriumchloride (NaCl) 0,9 percent (%), the spinal 27-gauge pencil point needle is advanced until it reaches the subarachnoidal space. Once the wright needle tip position is confirmed by back flow of cerebrospinal fluid (CSF), the local anesthetic solution will be injected in 15 seconds with the spinal needle orifice facing cephalad. Immediate after injection the epidural catheter will be inserted and placed at a distance of 5 cm beyond the Tuohy needle tip. Afterwards the patient is turned to the supine position A left lateral tilt (30%) will be applied to the operating table.
The Trendelenburg position of the table may be changed from -15 degree(°) to 15 ° table if necessary according to the anaesthetist in charge who is blinded for the appointed study group. In the unusual case of insufficient analgesia a single top-up dose of 5ml lidocaine 2% can be given through the epidural catheter. The bladder will be catheterized after spinal puncture. The start time of the recordings (T0) is the injection of the spinal anesthesia. At this moment we start the continuous infusion of norepinephrine. The anesthesiologist who performed the spinal anesthesia will leave the operating room and is replaced by a protocol trained second anesthesiologist to maintain blinding. The observer is always unaware of the appointed study group. He/she will titrate the continuous infusion of norepinephrine. In case of hypotension, defined as a decrease of 10% (more or equal) from baseline systolic arterial pressure, or an absolute value lower than( <) 100 mmHg, norepinephrine infusion will be increased with 2ml/hr each time with a maximum of 30ml/hr. Patients receive no extra volume loading besides a standard crystalloid infusion at a continuous rate of 80ml/u.
In case of hypertension, systolic blood pressure of more than 10% above baseline, the infusion will be lowered by 2ml/hr. Observation of vital parameters will be continued until safe delivery of the baby. Blood samples from the umbilical cord immediately after birth is part of standard of care.
With a non-inferiority margin of 0,05 we will need a sample size of 39 patients per group. Data will be collected using Redcap software to maximize transparency. Patient characteristics such as age and BMI will be compared with a two-sample T test to make sure that the two groups are equally representative.
All hemodynamic measurements such as heart rate and blood pressure will be compared with two-sample T-test. For ordinal variables such as Apgar scores and maternal nausea, a Wilcoxon-Mann Whitney test will be used. The occurrence of maternal vomiting will be compared using a Fisher's exact test.
- Being tested
- Norepinephrine
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NorepinephrineDrug
treatment of postspinal hypotension
NorepinephrineDrug
treatment of postspinal hypotension
| Study group | Role | What they receive |
|---|---|---|
| Group A | Active comparator | combined spinal epidural anesthesia (CSE) with 7,5mg hyperbaric Marcaine and 2,5mcg Sufentanil Receives: Drug: Norepinephrine |
| Group B | Active comparator | combined spinal epidural anesthesia (CSE) anesthesia with 10mg hyperbaric Marcaine and 2,5mcg Sufentanil Receives: Drug: Norepinephrine |
What is being measured
The primary outcome is the main question the study is designed to answer.
dose norepinephrine used in group A
dose in microgram of norepinephrine used for treatment of hypotension in both arms
Measured: from administration of spinal anesthesia until delivery of the newborn
dose norepinephrine used in group B
dose in microgram of norepinephrine used for treatment of hypotension in both arms
Measured: from administration of spinal anesthesia until delivery of the newborn
Secondary outcomes (1)
biochemical effect of norepinephrine on the newborn
deviation of normal mean arterial pH 7.26 of the newborn
Measured: bloodsample taken from umbilical cord at birth
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Mar 2022
- Study start9 Jun 2022
- Primary completion2 Mar 2023
- Study completion27 Aug 2025
Why it stopped: patient inclusion is too difficult
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cesarean Section ComplicationsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Norepinephrine infusion is given for treatment of postspinal hypotension in treatment group A and B
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 11 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Antwerp
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hilde Coppejans, University Hospital, Antwerp
- Investigators
- Hanne Ryckebosch, MD, Principal investigator, University Hospital, Antwerp
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05264870
- Sponsor's protocol ID
- 002105
- Status last verified
- Sep 2025
- First submitted
- 22 Feb 2022
- Last updated
- 10 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Norepinephrine as Hemodynamic Maintenance in Caesarian Delivery Under Spinal Anesthesia
- ClinicalTrials.gov ID
- NCT05264870
- Acronym / sponsor ID
- 002105
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: patient inclusion is too difficult
- Enrolment
- 11 participants (actual)
- Lead sponsor
- University Hospital, AntwerpUniversity, hospital or other
- Study start
- 9 Jun 2022 (actual)
- Primary completion
- 2 Mar 2023 (actual)
- Study completion
- 27 Aug 2025 (actual)
- First posted
- 3 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Postspinal hypotension is a frequent maternal complication in caesarian delivery under neuraxial anesthesia which is most commonly treated with the administration of phenylephrine infusion. In this trial, postspinal hypotension will be treated with norepinephrine. The main objective is to examine the pharmacodynamic and biochemical effect of norepinephrine both on mother and newborn.
Detailed description
Patients scheduled for routine elective cesarean section under combined spinal epidural anesthesia (CSE)will be enrolled in this double-blind, randomized controlled trial, As standard of care for cesarean section procedure, a preoperative anesthetic consultation is performed. If the patient is eligible for enrollment, she will be provided with detailed information regarding the study and asked to sign Informed Consent. Participants are allocated to one of two groups: Group A will receive a CSE anesthesia with 7,5 milligrams (mg)hyperbaric Marcaine and 2,5 microgram (mcg)Sufentanil.
Group B will receive a CSE anesthesia as well with 10 mg hyperbaric Marcaine and 2,5 mcg Sufentanil. At the University Hospital Antwerp, Group A is standard of care for cesarean section. In case of insufficient pain relief an extra bolus of local anesthesia through the epidural catheter can be administered in both groups. In this trial we use a double blinding principle. Both the patient and the observant/study physician are fully blinded. To maintain blinding of the study, two anesthesiologists are involved in this trial. The first anesthesiologist will perform randomization by means of Redcap software and will prepare study medication according to allocation to group A or B just before start of spinal anesthesia. He /she is responsible for the placement of neuraxial block and the spinal epidural catheter. As part of routine care anesthesia an intravenous line with 500 milliliter (ml) Plasmalyte (minimal 20 Gauche catheter) will be established in both groups . Standard monitoring (blood pressure, Electrocardiogram and Oxygen saturation) will be applied.
A baseline systolic blood pressure will be measured as a mean of 3 consecutive measurements before start of CSE and is defined as baseline blood pressure.
Blood pressure will be measured every 1 minute. To maintain normotension during the procedure a continuous infusion of norepinephrine will be given at 15 milliliter/hour through the peripheral intravenous (IV)catheter in both groups. Therefore a solution of norepinephrine in a concentration of 10mcg/ml in a 50ml syringe is prepared and connected to the peripheral IV line, most proximal to the IV catheter. A combined spinal epidural puncture will be performed in the sitting position at the level of Lumbal (L)2-L3 or L3-L4 with a CSE needle set (18 Gauge Tuohy needle, 27 Gauge pencil point needle, 18 gauge catheter, Braun).
After placing the 18-gauge Tuohy needle in the epidural space, confirmed by loss of resistance with natriumchloride (NaCl) 0,9 percent (%), the spinal 27-gauge pencil point needle is advanced until it reaches the subarachnoidal space. Once the wright needle tip position is confirmed by back flow of cerebrospinal fluid (CSF), the local anesthetic solution will be injected in 15 seconds with the spinal needle orifice facing cephalad. Immediate after injection the epidural catheter will be inserted and placed at a distance of 5 cm beyond the Tuohy needle tip. Afterwards the patient is turned to the supine position A left lateral tilt (30%) will be applied to the operating table.
The Trendelenburg position of the table may be changed from -15 degree(°) to 15 ° table if necessary according to the anaesthetist in charge who is blinded for the appointed study group. In the unusual case of insufficient analgesia a single top-up dose of 5ml lidocaine 2% can be given through the epidural catheter. The bladder will be catheterized after spinal puncture. The start time of the recordings (T0) is the injection of the spinal anesthesia. At this moment we start the continuous infusion of norepinephrine. The anesthesiologist who performed the spinal anesthesia will leave the operating room and is replaced by a protocol trained second anesthesiologist to maintain blinding. The observer is always unaware of the appointed study group. He/she will titrate the continuous infusion of norepinephrine. In case of hypotension, defined as a decrease of 10% (more or equal) from baseline systolic arterial pressure, or an absolute value lower than( <) 100 mmHg, norepinephrine infusion will be increased with 2ml/hr each time with a maximum of 30ml/hr. Patients receive no extra volume loading besides a standard crystalloid infusion at a continuous rate of 80ml/u.
In case of hypertension, systolic blood pressure of more than 10% above baseline, the infusion will be lowered by 2ml/hr. Observation of vital parameters will be continued until safe delivery of the baby. Blood samples from the umbilical cord immediately after birth is part of standard of care.
With a non-inferiority margin of 0,05 we will need a sample size of 39 patients per group. Data will be collected using Redcap software to maximize transparency. Patient characteristics such as age and BMI will be compared with a two-sample T test to make sure that the two groups are equally representative.
All hemodynamic measurements such as heart rate and blood pressure will be compared with two-sample T-test. For ordinal variables such as Apgar scores and maternal nausea, a Wilcoxon-Mann Whitney test will be used. The occurrence of maternal vomiting will be compared using a Fisher's exact test.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- Norepinephrine infusion is given for treatment of postspinal hypotension in treatment group A and B
| Arm | Type | Receives |
|---|---|---|
| Group A | Active comparator | Drug: Norepinephrinecombined spinal epidural anesthesia (CSE) with 7,5mg hyperbaric Marcaine and 2,5mcg Sufentanil |
| Group B | Active comparator | Drug: Norepinephrinecombined spinal epidural anesthesia (CSE) anesthesia with 10mg hyperbaric Marcaine and 2,5mcg Sufentanil |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- American Society of Anesthesiologists classification (ASA)1 and 2 patients
- non-laboring and singleton pregnancy
Key exclusion criteria (7 listed)
- patients with cardiovascular comorbidities
- any kind of cardiac and peripheral vascular disease or diabetes
- history of coagulopathy
- contra-indication to spinal anesthesia
- allergic condition to vasopressors or local anesthetics
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Norepinephrinetreatment of postspinal hypotension | Drug | Group A |
| Norepinephrinetreatment of postspinal hypotension | Drug | Group B |
Primary outcome
dose norepinephrine used in group A
Time frame: from administration of spinal anesthesia until delivery of the newborn
dose in microgram of norepinephrine used for treatment of hypotension in both arms
dose norepinephrine used in group B
Time frame: from administration of spinal anesthesia until delivery of the newborn
dose in microgram of norepinephrine used for treatment of hypotension in both arms
1 secondary outcome
biochemical effect of norepinephrine on the newborn
Time frame: bloodsample taken from umbilical cord at birth
Results and safety
The study was stopped early (reason given: patient inclusion is too difficult). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2025.
Related trials for Cesarean Section Complications
Not yet recruitingObservational study
Evaluation of Consciousness Depth (qCON) and Analgesia Depth (qNOX) Indices in General Anesthesia
Cesarean Section (MeSH: D002585), Anesthesia
Recruiting
Reducing Chronic Pain Following Cesarean Delivery
Chronic Pain, Cesarean Section Complications
Not yet recruiting
LI4 and SP6 Acupuncture for Pain After Cesarean Delivery
Acute Postoperative Pain After Cesarean Delivery
RecruitingPhase 4
Carbetocin Monotherapy Versus Carbetocin Plus Oxytocin Infusion in Elective Cesarean Delivery: A Non-Inferiority Trial
Postpartum Hemorrhage, Uterine Atony
Recruiting
Effects of Music Therapy, Breathing Exercises, and Virtual Reality on Obstetric Recovery, Pain, and Gastrointestinal Symptoms After Cesarean Section
Cesarean Section, Cesarean Section Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hanne Ryckebosch, MD principal investigator
University Hospital, Antwerp
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Norepinephrine in people with Cesarean Section Complications and Hemodynamic Instability, run by University Hospital, Antwerp at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 10 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: patient inclusion is too difficult). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
dose norepinephrine used in group A (time frame: from administration of spinal anesthesia until delivery of the newborn). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2025.